Menezes Maria N, Puri Prem
The National Children's Hospital, Dublin, Ireland.
Eur Urol. 2007 Nov;52(5):1505-9. doi: 10.1016/j.eururo.2007.04.082. Epub 2007 May 7.
Although endoscopic treatment provides a high rate of success in children with grades II-IV vesicoureteral reflux (VUR), its role in the management of grade V reflux has been questioned. In this study we reviewed our 21-yr experience of endoscopic treatment in children with grade V primary VUR.
We retrospectively reviewed the medical records of 132 children who underwent endoscopic treatment for primary grade V reflux from 1984 to 2004. VUR was unilateral in 39 patients and bilateral in 34, and 59 patients had ipsilateral grade V reflux with a lower grade of VUR on the contralateral side. Endoscopic treatment was performed in a total of 166 grade V ureters; polytetrafluoroethylene was used from 1984 to 2000 and dextranomer/hyaluronic acid from 2001 to 2004. Median follow-up was 12.2 yr and mean follow-up was 13.4 yr.
VUR was completely resolved after first injection in 88 (53%) ureters and downgraded to grade I or II in 26 (15.7%). VUR resolved after a second and third injection in 36 (21.7%) and 10 (6%) of ureters, respectively. Endoscopic treatment failed to correct VUR in 6 (3.6%) ureters, requiring ureteral reimplantation in 5 and nephrectomy in 1. Thirteen patients developed urinary tract infections during the follow-up period, and on investigation 9 ureters (5.4%) had recurrence of VUR. No injection or morbidity related to tissue-augmenting substances was noted in any patient.
Endoscopic treatment should be the first-line of treatment in management of grade V vesicoureteral reflux.
虽然内镜治疗在II-IV级膀胱输尿管反流(VUR)患儿中成功率较高,但其在V级反流管理中的作用一直受到质疑。在本研究中,我们回顾了21年来内镜治疗原发性V级VUR患儿的经验。
我们回顾性分析了1984年至2004年间接受内镜治疗原发性V级反流的132例患儿的病历。39例患者为单侧VUR,34例为双侧VUR,59例患者同侧为V级反流,对侧为较低级别的VUR。共对166条V级输尿管进行了内镜治疗;1984年至2000年使用聚四氟乙烯,2001年至2004年使用葡聚糖omer/透明质酸。中位随访时间为12.2年,平均随访时间为13.4年。
88条(53%)输尿管首次注射后VUR完全缓解,26条(15.7%)降至I级或II级。第二次和第三次注射后,分别有36条(21.7%)和10条(6%)输尿管的VUR缓解。6条(3.6%)输尿管的内镜治疗未能纠正VUR,其中5条需要输尿管再植,1条需要肾切除。13例患者在随访期间发生尿路感染,经检查9条输尿管(5.4%)出现VUR复发。未发现任何患者有与组织增强物质相关的注射或并发症。
内镜治疗应作为V级膀胱输尿管反流管理的一线治疗方法。